Table 1 Clinical characteristics of low EPC (CD133/Flk1+ < 0.0881%) and high EPC (CD133/Flk1+ > 0.0881%) groups
All patients (n = 101) | Low EPC group (n = 51) | High EPC group (n = 50) | P value | |
|---|---|---|---|---|
Demographics | ||||
Age, years | 66.96 (10.6) | 69.5 (8.8) | 64.4 (11.7) | 0.014 |
Male sex (%) | 69.3 | 68.6 | 70 | 0.881 |
HD vintage (years) | 5.91 (2.08–12.29) | 6.56 (3.26–11.58) | 5.00 (1.12–13.4) | 0.166 |
Inpatients (%) | 93.1 | 98.0 | 88.0 | 0.047 |
BMI (kg/m2) | 22.04 (3.94) | 22.16 (4.53) | 21.93 (3.27) | 0.769 |
Clinical measurements | ||||
Albumin (g/dL) | 2.98 (0.49) | 2.90 (0.49) | 3.06 (0.48) | 0.094 |
BUN (mg/dL) | 43.8 (16.0) | 43.8 (15.1) | 43.7 (16.9) | 0.979 |
Creatinine (mg/dL) | 8.19 (2.02) | 7.93 (1.91) | 8.44 (2.12) | 0.216 |
adjusted Ca (mg/dL) | 9.58 (0.79) | 9.65 (0.72) | 9.49 (0.84) | 0.306 |
Phosphate (mg/dL) | 4.22 (1.45) | 4.13 (1.32) | 4.32 (1.57) | 0.516 |
CRP (mg/dL) | 0.86 (0.21–3.11) | 1.44 (0.27–4.55) | 0.63 (0.15–1.69) | 0.017 |
WBC (/mm3) | 6100 (4900–7150) | 6200 (4900–7000) | 6050 (4300–7225) | 0.649 |
Hemoglobin (g/dL) | 9.97 (1.59) | 9.95 (1.71) | 9.99 (1.47) | 0.902 |
Serum iron (μg/dL) | 40.0 (27.5–63.5) | 39.0 (26.0–64.0) | 40.5 (30.0–57.0) | 0.831 |
TSAT (%) | 21.7 (12.7) | 21.5 (12.9) | 21.8 (12.6) | 0.909 |
Ferritin (ng/mL) | 118.8 (53.4–241.2) | 121.4 (62.7–245.4) | 117.3 (43.1–243.4) | 0.545 |
Glucose (mg/dL) | 144.4 (49.0) | 142.2 (34.5) | 146.7 (60.6) | 0.649 |
Total cholesterol (mg/dL) | 150.9 (43.3) | 148.0 (43.4) | 153.8 (43.4) | 0.503 |
Triglyceride (mg/dL) | 100.5 (45.4) | 102.2 (49.1) | 98.8 (41.8) | 0.709 |
Intact PTH (pg/mL) | 117.6 (63.2–207.6) | 113.8 (60.5–178.8) | 124.0 (63.8–217.0) | 0.386 |
BNP (pg/mL) | 338.7 (134.5–881.8) | 315.2 (151.0–1096) | 350.1 (99.6–815.1) | 0.325 |
SBP (mmHg) | 145.0 (26.9) | 140.5 (24.4) | 149.6 (28.8) | 0.088 |
DBP (mmHg) | 75.0 (14.79) | 72.3 (13.9) | 77.7 (15.3) | 0.068 |
Pulse rate (/min) | 75.5 (13.5) | 77.3 (15.0) | 73.7 (11.6) | 0.177 |
CD133/Flk1 + EPC (%) | 0.0880 (0.0370–0.1615) | 0.0393 (0.0264–0.0613) | 0.1615 (0.1168–0.3926) | < 0.001 |
CD34/Flk1 + EPC (%) | 0.0723 (0.0381–0.1502) | 0.0397 (0.0175–0.0687) | 0.1303 (0.0741–0.3755) | < 0.001 |
ERI (IU/week/kg/g/dL) | 18.4 (7.2–33.0) | 20.4 (8.0–46.7) | 15.6 (6.6–29.0) | 0.240 |
Comorbidities | ||||
Charlson index | 7.0 (6.0–9.0) | 8.0 (6.0–9.0) | 7.0 (6.0–9.0) | 0.210 |
CAD (%) | 23.8 | 29.4 | 18.0 | 0.178 |
CVD (%) | 17.8 | 19.6 | 16.0 | 0.636 |
PVD (%) | 23.8 | 29.4 | 18.0 | 0.178 |
CHF (%) | 27.7 | 33.3 | 22.0 | 0.203 |
Dementia (%) | 2.0 | 3.9 | 0 | 0.157 |
DM (%) | 49.5 | 52.9 | 46.0 | 0.485 |
Malignancy (%) | 23.8 | 25.5 | 22.0 | 0.680 |
Treatments | ||||
ESA dose (IU/week/kg) | 161.6 (75.0–320.9) | 179.0 (80.4–444.4) | 150.5 (71.0–285.1) | |
Epoetin (%) | 30.7 | 29.4 | 32.0 | 0.778 |
DA (%) | 64.4 | 70.6 | 58.0 | 0.187 |
CERA (%) | 5.0 | 0 | 10.0 | 0.021 |
Iron agent (%) | 36.6 | 43.1 | 30.0 | 0.171 |
Vitamin D (%) | 68.3 | 66.7 | 70.0 | 0.719 |
CaSR agonist (%) | 32.7 | 35.3 | 30.0 | 0.571 |